Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,288)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05757973 | Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Dec 9, 2025 | clinicaltrials |
| NCT05164250 | Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) | approved for marketing | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Nov 10, 2025 |
| clinicaltrials |
| NCT05463939 | Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 15, 2025 | clinicaltrials |
| NCT01833039 | An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | approved for marketing | — | — | Janssen Biotech, Inc.INDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT05172700 | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | approved for marketing | — | — | Loxo Oncology, Inc.INDUSTRY | 0 | Dec 18, 2024 | clinicaltrials |
| NCT05733650 | Expanded Access Program for Epcoritamab | approved for marketing | — | — | GenmabINDUSTRY | 0 | May 25, 2023 | clinicaltrials |
| NCT04162756 | Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies(ZUMA-18) | approved for marketing | — | — | Kite, A Gilead CompanyINDUSTRY | 1 | Oct 14, 2021 | clinicaltrials |
| NCT04943952 | JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 0 | Aug 3, 2021 | clinicaltrials |
| NCT04300803 | Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL | approved for marketing | — | — | MorphoSys AGINDUSTRY | 0 | Aug 28, 2020 | clinicaltrials |
| NCT01632826 | Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma(PEXIUS) | approved for marketing | — | — | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT02477891 | Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 6 | Jan 15, 2019 | clinicaltrials |
| NCT01410500 | Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease | approved for marketing | — | — | AmgenINDUSTRY | 0 | May 2, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Dec 9, 2025source: clinicaltrials